Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

India's vaccine output likely to fall short of target, sources say

Thu, 20th May 2021 13:14

By Neha Arora and Krishna N. Das

NEW DELHI, May 20 (Reuters) - India's output of COVID-19
shots for August-December is likely to be lower than the
government's public estimate, according to internal projections
shared with Reuters by two sources.

Lower-than-expected production could delay India's plans to
vaccinate all its adults this year, amid fears the country will
face another surge of coronavirus infections in the winter.
India's ongoing second wave, the world's worst since the
pandemic began, has overwhelmed its health system.

The government last week publicly estimated 1.46 billion
doses of its three approved shots - AstraZeneca, Sputnik
V and Covaxin - would be made between August and December.

Production of the AstraZeneca vaccine, of which the Serum
Institute of India (SII) is the biggest maker in the world, is
expected to reach 100 million to 110 million doses a month from
July and stay at that level for the foreseeable future, a source
with knowledge of the matter said.

That would be at least 200 million doses less than the
government's public forecast of 750 million AstraZeneca doses
for the last five months of the year, a 27% shortfall.

An internal government projection for August and September
shared by a second source put the monthly number of AstraZeneca
doses at 100 million, out of 200 million for all the three
approved shots combined.

The sources declined to be named discussing a subject on
which Prime Minister Narendra Modi's government has been
criticised due to a shortage of vaccines. Immunisations have
fallen https://dashboard.cowin.gov.in sharply since an April
peak.

The Ministry of Health and Family Welfare did not respond to
queries from Reuters.

SII, which is facing raw material shortages for another
vaccine that the government is banking on, declined to comment.

A spokeswoman for Covaxin-maker Bharat Biotech said that
last month the company raised its annual production capacity to
more than 500 million doses, or about 42 million doses a month.
It has been producing about 10 million doses a month.

Dr. Reddy's Laboratories, the local distributor
for Russia's Sputnik V, did not respond to a request for
comment.

Apart from the approved vaccines, the government has also
forecast August-December production of 866 million doses of five
yet-to-be-approved vaccines. Overall, the government has pledged
to make 2.67 billion doses available this year.

SII has already halted exports until the end of the year to
meet domestic demand, in a major blow to dozens of poor
countries relying on it for supplies.

India has so far administered 187 million vaccine doses, the
most after China and the United States, but fully immunised only
about 3% of its 1.35 billion people.

(Reporting by Neha Arora and Krishna N. Das; editing by
Philippa Fletcher)

More News
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more
21 May 2024 12:03

CORRECT: Stocks fall but pound up as IMF ups UK forecast

(Correcting London Stock Exchange index prices.)

Read more
21 May 2024 12:00

LONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast

(Alliance News) - Stock prices in Europe were lower heading into Tuesday afternoon, with shares in New York also set for a muted open, as a recent rally for equities takes a pause.

Read more
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
21 May 2024 09:04

LONDON MARKET OPEN: FTSE 100 declines after Asian stocks fall

(Alliance News) - Stock prices in London opened in the red on Tuesday, with some US interest rate cut optimism cooling after hawkish words from Federal Reserve central bankers.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.